Transaction DateRecipientSharesTypePriceValue
6th July 2020Jay Venkatesan9,310Exercise of derivative$0.65$6,051.50
6th July 2020Jay Venkatesan12,930Exercise of derivative$1.03$13,317.90
12th June 2020Chad A. Mirkin10,195Open or private sale$2.83$28,851.85
12th June 2020Llc Aurasense10,195Open or private sale$2.83$28,851.85
20th May 2020Chad A. Mirkin49,649Exercise of derivative$0.65$32,271.85
13th March 2020David R Walt54,064Open or private purchase$16.66$900,911.68
13th March 2020David R Walt291,066Open or private purchase$1.21$352,859.31
12th March 2020David S Snyder18,248Open or private purchase$1.40$25,591.00
12th March 2020Chad A. Mirkin15,000Open or private purchase$1.45$21,750.00
2nd January 2020David R Walt2,270Grant/award etc.$0.00
Exicure logo

Exicure, Inc. engages in the provision of clinical stage biotechnology company. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Ticker: XCUR
Sector: Commercial Services
Industry: Miscellaneous Commercial Services
SEC Central Index Key (CIK): 1698530
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $17 M (0%)
Assets, Current: $89 M (-20%)
Property, Plant and Equipment, Net: $4 M (0%)
Other Assets, Noncurrent: $2 M (0%)
Assets: $96 M (-16%)
Long-term Debt, Current Maturities: $0 (-100%)
Accounts Payable, Current: $2 M (-15%)
Accrued Liabilities, Current: $2 M (0%)
Liabilities, Current: $14 M (-53%)
Liabilities: $14 M (-58%)
Common Stock, Value, Issued: $9 Th (0%)
Common Stock, Shares, Issued: $87 M (0%)
Retained Earnings (Accumulated Deficit): $84 M (3%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $338 Th (1151%)
Stockholders' Equity (Parent): $82 M (0%)
Liabilities and Equity: $96 M (-16%)
Revenue: $5 M (-65%)
Research and Development: $7 M (-46%)
General and Administrative Expenses: $2 M (-53%)
Operating Income/Loss: $4 M (13%)
Other Income, net: $79 Th (-88%)